𝐈𝐬 𝐓𝐃𝐏-𝟒𝟑 𝐭𝐡𝐞 𝐥𝐲𝐧𝐜𝐡𝐩𝐢𝐧 𝐟𝐨𝐫 𝐟𝐢𝐧𝐝𝐢𝐧𝐠 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐟𝐨𝐫 𝐀𝐋𝐒? Two pathologies, one protein The field has increasingly recognized that TDP-43 dysfunction operates through two parallel mechanisms. The cytoplasmic gain-of-function toxicity that CTx1000 directly targets is only half the story. Equally consequential is the loss of normal nuclear TDP-43 function, particularly its role in RNA splicing regulation: nuclear depletion of TDP-43 leads to the inclusion of unannotated or cryptic exons in transcripts encoding key neuronal survival regulators, including STMN2 and UNC13A.

This splicing dysregulation, observed in patient postmortem tissue, might be a driver of neurodegeneration that is at least as proximal as cytoplasmic aggregation itself, and antisense oligonucleotides (ASOs) designed to correct UNC13A cryptic splicing have already been shown to rescue synaptic function in TDP-43-depleted human neurons, providing independent, complementary evidence for the causal importance of TDP-43 loss-of-function.

A therapy that clears cytoplasmic aggregates without restoring nuclear splicing function – or, worse, one that inadvertently exacerbates nuclear depletion – might produce incomplete or even detrimental clinical outcomes. CTx1000’s 14-3-3θ/degron design was purposely engineered to preserve functional nuclear TDP-43 while removing the harmful cytoplasmic form. However, the underlying mechanistic selectivity has so far been demonstrated as preferential rather than absolute – the fusion protein shows higher affinity for pathological versus physiological TDP-43, rather than binding pathological TDP-43 exclusively – and its behavior in aged human neurons remains an open empirical question.

One line of evidence supporting a causal role for TDP-43 in disease is the existence of pathogenic mutations in the gene encoding TDP-43 itself, TARDBP, in a subset of familial ALS.(p14) These rare mutations demonstrate that TDP-43 dysfunction can be sufficient to cause motor neuron disease, although whether they model the far more common sporadic proteinopathy remains uncertain. Some TARDBP mutations seem to enhance cytoplasmic aggregation, whereas others primarily impair nuclear localization and splicing activity, so the existence of the mutations does not by itself resolve the gain-of-function versus loss-of-function debate.

A secondary concern warrants clear recognition. If TDP-43 aggregation is not a cause but a marker of upstream problems, then removing it – even selectively – might leave the root cause of neurodegeneration untouched. This structural risk echoes the adjuvant paradox in neuroinflammatory disease, where clearing protective protein deposits without resolving the underlying substrate dismantles a sequestration response, leaving the toxic agent free to accelerate injury.

Whether cytoplasmic TDP-43 aggregates similarly perform any protective sequestration function is, at present, an unresolved and largely unc